(3aR)-Selitrectinib

CAS No. 1350884-56-8

(3aR)-Selitrectinib( BAY 2731954 | (6RS)-LOXO-195 )

Catalog No. M28716 CAS No. 1350884-56-8

(6RS)-LOXO-195 is a potent and selective Trk tyrosine kinase inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 43 Get Quote
5MG 72 Get Quote
10MG 110 Get Quote
25MG 215 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    (3aR)-Selitrectinib
  • Note
    Research use only, not for human use.
  • Brief Description
    (6RS)-LOXO-195 is a potent and selective Trk tyrosine kinase inhibitor.
  • Description
    (6RS)-LOXO-195 is a potent and selective Trk tyrosine kinase inhibitor.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    BAY 2731954 | (6RS)-LOXO-195
  • Pathway
    Tyrosine Kinase
  • Target
    Trk Receptor
  • Recptor
    Apoptosis|MARK3|MARK4
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1350884-56-8
  • Formula Weight
    380.427
  • Molecular Formula
    C20H21FN6O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    [H][C@]12CCCN1c1ccn3ncc(C(=O)NC(C)CCc4ncc(F)cc24)c3n1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Fangfang Li, et al. PCC0208017, a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression?in vitro?and?in vivo. Acta Pharm Sin B.2020 Feb;10(2):289-300.
molnova catalog
related products
  • ALE-0540

    ALE-0540 is a nerve growth factor (NGF) antagonist that inhibits the binding of NGF to TrkA or both p75 and TrkA with IC50 of 5.88 and 3.72 uM, respectively.

  • LOXO-101 sulfate

    LOXO-101 (ARRY-470, Larotrectinib) is potent, selective pan-TRK inhibitor with cellular IC50 of 2-20 nM against TRKA, TRKB, and TRKC kinases.

  • GZ389988

    GZ389988 (GZ-389988) is a novel potent, selective, locally delivered TrkA inhibitor for the treatment osteoarthritis; shows similar IC50 values for TrkA, TrkB and TrkC, and the growth factor receptor cFMS (CSF1R).